Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | MMP7 | P09237 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21814588 | 1.00 | HTT (0.49) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL19404003 | 0.90 | HTT (0.54) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL10780607 | 0.86 | ADAMTS4 (0.54) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL24211175 | 0.85 | HSD17B10 (0.50) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL9764157 | 0.84 | HTT (0.49) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL9706817 | 0.81 | HTT (0.65) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL7776370 | 0.81 | HTT (0.65) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL7889040 | 0.80 | TSHR (0.58) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL25269775 | 0.80 | TSHR (0.58) | HTTHSD17B10TSHRALDH1A1HPGD | |
| SCHEMBL7138463 | 0.80 | TSHR (0.58) | HTTHSD17B10TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240060977-A1 | USE OF BIOMARKERS FOR PREDICTING THE CLINICAL AND/OR TREATMENT OUTCOME OF A HUMAN SUBJECT | ALPSPITZ BIOSCIENCE GMBH (DE) | 2024-02-22 | — | — | US | disclosed |
| EP-4275043-A1 | USE OF BIOMARKERS FOR PREDICTING THE CLINICAL AND/OR TREATMENT OUTCOME OF A HUMAN SUBJECT | Alpspitz Bioscience GmbH (DE) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022148866-A1 | USE OF BIOMARKERS FOR PREDICTING THE CLINICAL AND/OR TREATMENT OUTCOME OF A HUMAN SUBJECT | ALPSPITZ BIOSCIENCE GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| US-20220017942-A1 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF ACTIVE LEUKOCYTE CELLS USING AN ELECTROCHEMICAL ASSAY | CLEU DIAGNOSTICS, LLC | 2022-01-20 | — | — | US | disclosed |
| US-20210371898-A1 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF ACTIVE LEUKOCYTE CELLS USING AN ELECTROCHEMICAL ASSAY | CLEU DIAGNOSTICS, LLC | 2021-12-02 | — | — | US | disclosed |
| EP-3856710-A1 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF ACTIVE LEUKOCYTE CELLS USING AN ELECTROCHEMICAL ASSAY | Parvizi Surgical Innovation, LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210171467-A1 | REDOX SUBSTRATES FOR LEUKOCYTE ESTERASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020069176-A1 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF ACTIVE LEUKOCYTE CELLS USING AN ELECTROCHEMICAL ASSAY | PARVIZI SURGICAL INNOVATION, LLC (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017942-A1 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF ACTIVE LEUKOCYTE CELLS USING AN ELECTROCHEMICAL ASSAY | MPO, LPO, EPX | HTT 1518/4885HSD17B10 1028/4885TSHR 4238/4885 |
| US-20210371898-A1 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF ACTIVE LEUKOCYTE CELLS USING AN ELECTROCHEMICAL ASSAY | MPO, LPO, EPX | HTT 1518/4885HSD17B10 1028/4885TSHR 4238/4885 |
| US-20210171467-A1 | REDOX SUBSTRATES FOR LEUKOCYTE ESTERASE | LPO, MPO, EPX | HTT 4133/4885HSD17B10 123/4885TSHR 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.